The expression of two immunosuppressive SIGLEC family molecules in papillary thyroid cancer and their effect on prognosis

[1]  Hesong Wang,et al.  Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas , 2022, Frontiers in Genetics.

[2]  Chao Chen,et al.  Unveiling the molecular features, relevant immune and clinical characteristics of SIGLEC15 in thyroid cancer , 2022, Frontiers in Immunology.

[3]  X. Lan,et al.  Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma , 2022, Disease markers.

[4]  Zhaohui Lu,et al.  Analysis of a novel immune checkpoint, Siglec‐15, in pancreatic ductal adenocarcinoma , 2022, The journal of pathology. Clinical research.

[5]  Han Guo,et al.  Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samples , 2022, Frontiers of Medicine.

[6]  Midie Xu,et al.  Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer. , 2021, Acta biochimica et biophysica Sinica.

[7]  Chunyan Li,et al.  Identification and validation of an immune-related prognostic signature and key gene in papillary thyroid carcinoma , 2021, Cancer Cell International.

[8]  Xiao-dong Zhu,et al.  Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma , 2021, Experimental Hematology & Oncology.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  M. Pereira,et al.  Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters , 2021, European journal of histochemistry : EJH.

[11]  Libo Jiang,et al.  Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis , 2021, Annals of translational medicine.

[12]  Yang Ding,et al.  Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma , 2020, World journal of gastrointestinal oncology.

[13]  Zong Zhuang,et al.  Long-Term Elevated Siglec-10 in Cerebral Spinal Fluid Heralds Better Prognosis for Patients with Aneurysmal Subarachnoid Hemorrhage , 2020, Disease markers.

[14]  N. Nilubol,et al.  New Therapies for Advanced Thyroid Cancer , 2020, Frontiers in Endocrinology.

[15]  P. Ascierto,et al.  PD-1 Blockade in Anaplastic Thyroid Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Hongyang Wang,et al.  Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade , 2020, Frontiers in Immunology.

[17]  G. Adema,et al.  Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment. , 2020, Trends in immunology.

[18]  Sheng-Li Yang,et al.  Integrative Analysis of Siglec-15 mRNA in Human Cancers Based on Data Mining , 2020, Journal of Cancer.

[19]  X. Ren,et al.  Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis , 2020, Oncoimmunology.

[20]  Rachel E. Brewer,et al.  CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy , 2019, Nature.

[21]  Xu Zhou,et al.  Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy , 2019, Nature Medicine.

[22]  P. Validire,et al.  The clinical role of the TME in solid cancer , 2018, British Journal of Cancer.

[23]  C. Amos,et al.  Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells , 2018, The Journal of clinical investigation.

[24]  Michael Q. Zhang,et al.  Co‐inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor‐Infiltrating Myeloid Cells Induces Dysfunction of Anti‐tumor CD8+ T Cells , 2018, Immunity.

[25]  Shelly Maman,et al.  A history of exploring cancer in context , 2018, Nature Reviews Cancer.

[26]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[27]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[28]  S. Devesa,et al.  Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013 , 2017, JAMA.

[29]  L. Ni,et al.  Immune checkpoint receptors in cancer: redundant by design? , 2017, Current opinion in immunology.

[30]  C. Ki,et al.  Comprehensive screening for PD-L1 expression in thyroid cancer. , 2017, Endocrine-related cancer.

[31]  Todd M. Allen,et al.  The epigenetic landscape of T cell exhaustion , 2016, Science.

[32]  S. Berger,et al.  Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade , 2016, Science.

[33]  J. Fagin,et al.  Biologic and Clinical Perspectives on Thyroid Cancer. , 2016, The New England journal of medicine.

[34]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[35]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[36]  Florian Klemm,et al.  Microenvironmental regulation of therapeutic response in cancer. , 2015, Trends in cell biology.

[37]  Mithat Gonen,et al.  Nomograms in oncology: more than meets the eye. , 2015, The Lancet. Oncology.

[38]  K. Tao,et al.  Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma. , 2015, The Journal of surgical research.

[39]  G. Beatty,et al.  Immune Escape Mechanisms as a Guide for Cancer Immunotherapy , 2014, Clinical Cancer Research.

[40]  J. Paulson,et al.  Siglec-mediated regulation of immune cell function in disease , 2014, Nature Reviews Immunology.

[41]  K. Ohtsubo,et al.  The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway. , 2013, Glycobiology.

[42]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[43]  Mitsuru Nakamura,et al.  Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. , 2007, Glycobiology.

[44]  K. Cheng,et al.  A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33. , 2001, European journal of biochemistry.

[45]  P. Moore,et al.  Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor. , 2001, The Biochemical journal.

[46]  Shi-Shuai.  Identi cation of Lipid Metabolism-Related Genes as Prognostic Indicators in Papillary Thyroid Cancer , 2021 .

[47]  R. Scolyer,et al.  Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.

[48]  M. Zeiger,et al.  BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Cancer , 2012, Annals of Surgical Oncology.